Charged Alpha Stock Encyclopedia

Molina Healthcare (MOH) Q2 2026 — Molina Healthcare (MOH), a pure-play government-sponsored managed-care insurer (~4.9M members across Medicaid, Medicare, and the ACA marketplace; ~$42B premiums, ~1% pretax margin at the trough), reported Q2 2026 adjusted EPS of $1.51, beating the ~$1.40 estimate — but down 72% from $5.48 a year ago, with GAAP EPS just $1.19 (−75%). Revenue fell ~4.8% to $10.9B. The consolidated medical care ratio rose to 92.2% (from 90.4%) — still climbing YoY (Medicaid 92.7%, Medicare 90.7% beat, Marketplace 88.9% up 350bps). Molina RAISED full-year 2026 adjusted EPS guidance to at least $5.25 (from $5.00), but it was low-quality: a +$1.50 Medicare improvement was fully offset by a −$1.50 fresh Marketplace cut (ex-Marketplace it would be $6.75). The stock — which had more than doubled off a $121 low to ~$245 — FELL ~9% to ~$201 on the print, and was recently demoted from the S&P 500 to the MidCap 400. Our normalized owner-earnings DCF lands fair value near $185. Our call: HOLD.

Molina Healthcare is a pure-play government-sponsored health insurer — Medicaid (its core), Medicare (pivoting to dual-eligibles), and the Obamacare marketplace — covering ~4.9 million members on ~$42B of premiums, at razor-thin margins (~1% pretax at the trough). Q2 2026 looked like a beat-and-raise: adjusted EPS of $1.51 topped the ~$1.40 estimate, and management RAISED full-year 2026 adjusted guidance to at least $5.25. But the stock fell ~9% anyway — because underneath, earnings are down ~75% YoY (GAAP EPS $1.19; adjusted $1.51 vs $5.48 a year ago), the consolidated medical care ratio is still RISING (92.2% vs 90.4%), and the 'raise' was hollow: a +$1.50 Medicare gain was wiped out by a −$1.50 fresh Marketplace cut — the very segment that blew up guidance through 2025, when Molina guided $24.50 for the year and delivered ~$11. The bull case: 2026 is a genuine earnings trough — Medicaid rates are catching up, Medicare beat, ~$2.50/share of temporary drags (a Florida Medicaid startup and a Medicare drug-plan exit) reverse in 2027, and the Street models earnings rebounding ~80% next year, so on normalized profits the stock isn't expensive. The bear case: the consolidated MCR hasn't actually peaked, Marketplace is shrinking (−59% members) AND worsening into an ACA-subsidy cliff, management's credibility is shot after missing 2025 by half, and the stock has already doubled off its $121 low. Our normalized owner-earnings DCF — weighted toward the cautious path because the ratio is still rising and credibility is thin — lands fair value near $185, modestly below the ~$201 price. Tellingly, Wall Street isn't bullish either: ratings are split and the average target sits around $200, essentially at today's price. Our call: HOLD, 3/5, leaning cautious — a credible trough story, but an unproven one that's already priced for its own recovery. Watch the medical care ratio; add on real weakness in the mid-to-low $100s. Not financial advice.

THE CALL: HOLD (3/5, A CREDIBLE TROUGH STORY, BUT UNPROVEN AND ALREADY PRICED) — base-case value ~$185 vs ~$201 today.

What to watch: the consolidated medical care ratio actually falling across two or three clean quarters, with the Marketplace book no longer surprising — the proof that costs have peaked and the earnings recovery is real, which would prompt an upgrade; the risk to respect is another guidance cut, which would repeat the 2025 pattern ($24.50 guided, ~$11 delivered) and unwind the entire trough thesis

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Knight-Swift Transportation Holdings (KNX) Q2 2026 — Knight-Swift Transportation (KNX), the largest full-truckload carrier in North America, reported a Q2 2026 that signals the multi-year freight recession is finally inflecting: adjusted diluted EPS of $0.63 beat the ~$0.51 estimate (+80% YoY) on revenue of $2.10B (+12.6%), as the consolidated adjusted operating ratio improved 240 bps to 91.4% and adjusted operating income jumped 46% to $151M. (GAAP EPS was $0.26 — roughly half the adjusted figure — after items like ~$18M of executive severance tied to Kevin Knight's retirement and a US Xpress mark-to-market.) The beat was cyclical, not cosmetic: Truckload's adjusted OR improved 360 bps to 91.0% (adj. operating income +69%) as revenue per loaded mile accelerated from low-single-digits to high-single-digits by June (over-the-road rates +double digits in June) and tender rejections ran ~2x public indicators; Intermodal swung back to profit (OR 99.4% from 104%, loads +19.6%); and insurance/claims actually rose 17.5%, so this wasn't a friendly reserve release. LTL — the strategic growth engine — paused (revenue ex-fuel -1.4%) as management deliberately metered volume to lift weight per shipment (+7.9%). KNX guided Q3 adjusted EPS to $0.71-$0.77 (above the ~$0.71 Street) and the Truckload adjusted OR to improve 650-750 bps YoY — nearly double Q2's pace — with CEO Adam Miller framing the rate recovery as just beginning (early-year bids only now repricing to a tighter market). The dividend was raised 11% to $0.20/qtr (~1.1% yield); net debt is ~$2.2B (refinanced into $1.5B of 1% convertible notes due 2031); 1H free cash flow was ~$190M. But the stock has nearly doubled off its $38.63 low to ~$76, just shy of its $82.86 52-week high, pricing much of the recovery in. Our owner-earnings DCF, normalized to a ~$620M/yr mid-cycle base, lands fair value near $68 — about 11% below the price. Our call: HOLD, 3/5 — a real, accelerating freight-cycle turn in a quality operator, but no margin of safety at a 52-week high. We're more cautious than the Street's Buy (avg target ~$86, +13%).

Knight-Swift is the largest full-truckload carrier in North America and a genuine bellwether for the physical economy — and its Q2 2026 is the print freight investors have waited years for. Adjusted diluted EPS of $0.63 beat the ~$0.51 estimate (+80% YoY) on revenue of $2.10B (+12.6%), the consolidated adjusted operating ratio improved 240 bps to a recovering 91.4%, and adjusted operating income jumped 46% to $151M — a sharp sequential leap from just $0.09 last quarter. Crucially, the beat was cyclical, not cosmetic: Truckload's adjusted OR improved 360 bps to 91.0% (operating income +69%) as revenue per loaded mile accelerated from low-single-digits to high-single-digits by June and tender rejections ran ~2x public indicators; Intermodal returned to profitability (OR 99.4% from 104%, loads +19.6%); and insurance/claims actually rose 17.5%, so the earnings quality is real, not a reserve release. Management guided Q3 adjusted EPS to $0.71-$0.77 (above the ~$0.71 Street) and the Truckload adjusted OR to improve 650-750 bps YoY — nearly double Q2's pace — with CEO Adam Miller framing the up-cycle as only beginning. So the debate isn't the quarter. The stock has nearly doubled off its $38.63 low to ~$76, just shy of its $82.86 52-week high, and much of the freight recovery is already in the price — LTL growth paused (revenue ex-fuel -1.4%), insurance keeps biting, and GAAP earnings are less than half the adjusted headline. Value KNX on normalized, mid-cycle owner earnings (a ~$620M/yr base, ~$3.80/share) and our DCF lands fair value near $68 — only the full-recovery path exceeds today's price, and the 50/50 blend sits ~11% below it. Our call: HOLD, 3/5 — a top-tier operator riding a genuine, accelerating freight-cycle turn, but with no margin of safety at a 52-week high. We're more cautious than the Street's Buy consensus (avg target ~$86, +13%). Own it for the quality on a pullback toward the low-to-mid $60s; don't chase the cyclical at the top. Not financial advice.

THE CALL: HOLD (3/5, A REAL, ACCELERATING FREIGHT-CYCLE TURN — BUT NO MARGIN OF SAFETY AT A 52-WEEK HIGH) — base-case value ~$68 vs ~$76 today.

What to watch: freight rates tightening faster than the guide implies — truckload revenue per loaded mile and tender-rejection rates continuing to accelerate, pushing normalized earnings past our mid-cycle estimate — or the LTL build-out inflecting into real profit growth, either of which would let KNX grow into its multiple and could prompt an upgrade; the risk to respect is the freight recovery stalling, which at roughly 20x normalized earnings near a 52-week high could re-rate the stock hard toward our ~$68 fair value

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

STMicroelectronics (STM) Q2 2026 — STMicroelectronics (STM), one of Europe's largest chipmakers, reported a recovery quarter for Q2 2026: net revenue rose 26% YoY (and ~13% QoQ) to $3.49B — a touch ahead of estimates — as the deep automotive/industrial downturn finally turned. GAAP gross margin recovered to 34.8% (35.2% non-GAAP) and operating income swung to a $187M profit (5.4% margin) from a loss a year ago; net income was $222M ($0.24 GAAP, $0.31 non-GAAP). But the recovery is uneven: growth was led by Microcontrollers (+36%) and RF & Optical (+32%) riding AI-datacenter and comms demand, while the automotive/industrial Power & Discrete segment grew just ~4% and lost $99M (a −21% operating margin) as Chinese pricing pressure persists. Management guided Q3 revenue to $3.70B (+16% YoY) with gross margin stepping to 37%, and Q4 above $4B, raising its datacenter ambition to >$1B in 2026 and >$2B in 2027. The balance sheet is a fortress — ~$2.0B net cash — but trailing free cash flow was negative ~$261M (Q2 FCF just $75M), and the $0.36 dividend (~$320M/yr) isn't covered by trailing FCF. The stock has tripled off its $21 low to ~$66 (52-wk high $81), trading near 50x this year's expected earnings. The catch: even our recovery-leaning owner-earnings DCF lands fair value near $54. Our call: HOLD.

STMicroelectronics is one of Europe's crown-jewel chipmakers — a ~$59B French-Italian integrated device maker whose sensors, microcontrollers and power chips run your car, your factory, and increasingly the AI data center. Q2 2026 was a genuine recovery quarter: net revenue rose 26% YoY (~13% QoQ) to $3.49B, gross margin recovered to 34.8% (35.2% non-GAAP), and GAAP operating income swung to a $187M profit (5.4% margin) from a loss a year ago; net income was $222M ($0.24 GAAP, $0.31 non-GAAP). But this is a messy recovery, and that's the whole episode. The growth was led by the parts you might not expect — Microcontrollers (+36%) and RF & Optical (+32%), both riding AI-datacenter and communications demand — while the automotive/industrial Power & Discrete franchise, the cyclical heart of the bull thesis, grew just ~4% and actually lost MORE money ($99M, a −21% margin) as Chinese pricing pressure bites. So the classic broad auto/industrial rebound investors are paying for hasn't really arrived. Management guided Q3 revenue to $3.70B (GM to 37%) and Q4 above $4B, and raised its datacenter ambition to >$1B in 2026 and >$2B in 2027 — a real new growth leg. The balance sheet is a fortress (~$2.0B net cash), but trailing free cash flow was NEGATIVE ~$261M (Q2 FCF just $75M), and the flat-since-2023 $0.36 dividend (~$320M/yr) has been paid out of the balance sheet, not free cash flow. The stock has tripled off its $21 low to ~$66 (52-wk high $81) and trades near 50x this year's expected earnings — with gross margin (34.8%) still barely two-thirds of its ~48% peak and operating margin (5.4%) a fraction of its old ~26%. STM is maybe a quarter of the way back. Even normalizing owner earnings and leaning to the optimistic recovery path (12% FCF growth) at a fair 9% discount rate, our DCF lands fair value near $54 — meaningfully below the price. Our call: HOLD, 3/5. A good European franchise, a real recovery, and a net-cash balance sheet — but the recovery is already priced in, and the core is still bleeding. We're more cautious than the Street's ~$75 average target (Buy, ~15 of 29 analysts, +14% implied). Own it for the recovery on a pullback toward the mid-$40s; don't chase it here. Not financial advice.

THE CALL: HOLD (3/5, A REAL RECOVERY, ALREADY PRICED IN — THE CORE POWER FRANCHISE IS STILL LOSING MONEY) — base-case value ~$54 vs ~$66 today.

What to watch: hard evidence the recovery is broadening beyond AI/comms into the core — Power & Discrete clawing back toward breakeven, gross margin marching past its old ~48% peak as fab utilization normalizes, and pricing (especially in Chinese-pressured power chips) stabilizing — which would justify the ~50x multiple and prompt an upgrade; the risk to respect is the automotive/industrial recovery stalling or power pricing worsening, which at ~50x forward earnings and negative trailing free cash flow could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Southwest Airlines (LUV) Q2 2026 — Southwest Airlines (LUV), the low-fare giant remaking itself under activist Elliott, reported a strong Q2 2026 — its first full quarter with the entire transformation live. ADJUSTED EPS of $0.94 nearly doubled the ~$0.51 estimate (adjusted net income $465M), on record operating revenue of $8.4B GAAP (+16.4%, an all-time high) / $8.7B adjusted (+20.3%). On a GAAP basis, net income was $233M, or $0.47 a share, a 3.4% operating margin; adjusted operating margin roughly doubled to 6.7% — despite an $889M (~$1.17/share) fuel headwind at $3.92/gal. The revenue engine is clearly working: managed business +30%, Rapid Rewards enrollments +35% (~100M members), Chase co-brand acquisitions +28%, adjusted unit revenue +20.1%. But management TRIMMED full-year adjusted-EPS guidance to $3.25–$4.25 (from at least $4.00), and the stock fell ~2% to ~$47.66. On our EV/EBITDAR work (TTM adjusted EBITDAR ~$3.25B, a fortress 2.1x adjusted-debt/EBITDAR balance sheet), base-case fair value lands ~$50 — roughly fair value. Our call: HOLD.

Southwest Airlines is in the middle of the boldest reinvention in its 50-year history — under activist Elliott, it added assigned seats, extra-legroom rows, basic economy, and, for the first time ever, checked-bag fees, ending its most famous promise. Q2 2026 was the first full quarter with all of it live, and on the top line it's clearly working. ADJUSTED EPS of $0.94 nearly DOUBLED the ~$0.51 estimate (adjusted net income $465M) on record revenue — $8.4B GAAP (+16.4%, an all-time high) and $8.7B adjusted (+20.3%) — with adjusted operating margin roughly doubling to 6.7% despite a brutal $889M / ~$1.17-per-share fuel headwind ($3.92/gal). The transformation levers are all firing: managed business +30% (a record), Rapid Rewards enrollments +35% (nearly 100M members), Chase co-brand card acquisitions +28%, adjusted unit revenue +20.1%. So why did the stock FALL ~2%? Two reasons. First, on a GAAP basis this reinvention is still expensive and still early — net income was just $233M ($0.47/share) at a thin 3.4% operating margin, and management TRIMMED full-year adjusted-EPS guidance to $3.25–$4.25, down from at least $4.00. Second, even after doubling, Southwest's ~6.7% adjusted operating margin is still roughly HALF of Delta's and United's — this remains, structurally, a lower-margin airline. The one thing nobody disputes is the balance sheet: $5.3B of liquidity and just 2.1x adjusted-debt-to-EBITDAR, the strongest among the major U.S. carriers. Because airlines are capital- and lease-heavy, we value LUV on EV/EBITDAR (which adds aircraft rent back to cash profit). TTM adjusted EBITDAR is ~$3.25B; the transformation targets ~$4B of incremental EBIT by 2027. On a bear/base/bull EBITDAR grid at 5.0–6.0x, netting out ~$3.1B of adjusted debt, our base case (~$5.0B EBITDAR at 5.5x) lands fair value ~$50 vs ~$48 today — roughly fair value, with a bear case in the low $40s and a bull past $60. Our call: HOLD, 3/5 — a real turnaround, but already fairly priced. We're right in line with the Street's Hold consensus (~$52 average target). Watch adjusted unit revenue vs unit cost, the operating-margin gap to Delta and United, and fuel — those decide whether the $4B plan truly lands. Not financial advice.

THE CALL: HOLD (3/5, A REAL TURNAROUND, ALREADY FAIRLY PRICED — RECORD REVENUE AND A NEAR-DOUBLE BEAT, BUT THIN MARGINS VS PEERS AND A TRIMMED GUIDE) — base-case value ~$50 vs ~$47.66 today.

What to watch: proof the transformation is converting into durable margins — adjusted operating margins climbing toward double digits, the ~$4B incremental-EBIT plan showing up in reported results, and fuel behaving — would justify an upgrade; the risks to respect are a fuel spike, a demand slowdown, or evidence that bag fees and assigned seats are driving loyal flyers away, any of which hits a still-thin-margin airline hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

QuantumScape (QS) Q2 2026 — QuantumScape (QS), the solid-state lithium-metal battery developer, reported Q2 2026 (quarter ended June 30) on July 22: a GAAP net loss of $98.2M, or -$0.16/share (beat the -$0.18 estimate; improved from -$0.20 a year ago), and an adjusted EBITDA loss of $64.2M (~flat YoY). Crucially, QuantumScape remains PRE-REVENUE: it booked $0 GAAP revenue (some data feeds erroneously show ~$29.5M). What it actually reported was $10.8M of 'customer billings,' an operational metric it explicitly says is NOT revenue under GAAP. The real story is the balance sheet: $859M in cash + marketable securities and almost no debt, against a net burn near $56M/quarter — a runway well into ~2029. Q2 also brought real validation: a new multi-year Honda partnership (a 4th Top-10 OEM alongside Volkswagen's PowerCo), an amended PowerCo license, the Eagle Line pilot hitting >90% tool uptime (output doubling in H2), a QSE-5 shipment to a major American defense prime, and a reorg into three verticals — QSEV (EVs), QSDC (AI data centers), QSAS (aerospace/defense). Full-year adjusted-EBITDA-loss guidance was reiterated at $250-275M and capex cut to $27-37M. The stock has collapsed ~69% from a 52-week high near $19 to ~$5.87 (~44% YTD), a ~$3.6B market cap. Our reverse-DCF base case lands near $6 — roughly today's price — with a bear ~$2 and bull ~$12+. Our call: HOLD, 2/5.

QuantumScape is the market's ultimate high-risk, high-reward battery moonshot — a pre-commercial company chasing the solid-state, anode-free lithium-metal cell that could reshape the electric car. Q2 2026 delivered genuine progress: a new multi-year Honda partnership (a 4th Top-10 automaker alongside Volkswagen's PowerCo), the Eagle Line pilot line hitting >90% tool uptime with output set to double in H2, a QSE-5 cell shipment to a major American defense prime, and a reorg into three verticals — EVs (QSEV), AI data centers (QSDC), and aerospace/defense (QSAS). The loss is narrowing (net loss $98.2M, -$0.16/share, a beat), and the balance sheet is a fortress: $859M in cash and marketable securities against ~$56M/quarter of net burn, a runway into ~2029. But here's the catch that defines the whole thesis — QuantumScape still has ZERO GAAP revenue (the ~$29.5M some feeds show is an error; the company reported $10.8M of 'customer billings' it explicitly says is not revenue). Volume commercial cells from PowerCo aren't expected until ~2028, the hyped ~$130M royalty prepayment is still milestone-gated and unpaid, and shareholders are diluted a little more each quarter. Strip out the cash and the market values the business at ~$2.8B — implying QuantumScape builds a royalty stream of ~$250-350M/year (100+ GWh of licensed production) by the early 2030s, a demanding bar. Our reverse-DCF: bear ~$2, base ~$6, bull ~$12+, prob-weighted ~$6 — right about the ~$5.87 price. The stock has already been cut ~69% from its $19 high, so a lot of hype is gone, but there's no floor below net cash and the outcome is binary. Our call: HOLD, 2/5 — a de-rated moonshot that's validated and funded but still pre-revenue. We're aligned with the Street's Hold, just a touch more cautious on value. Own it small, size it for a binary outcome, and wait for commercialization proof. Not financial advice.

THE CALL: HOLD (2/5, A DE-RATED MOONSHOT — VALIDATED, FUNDED, BUT STILL PRE-REVENUE) — base-case value ~$6 vs ~$5.87 today.

What to watch: hard commercialization proof would turn us more bullish — PowerCo triggering the ~$130M royalty prepayment, the Eagle Line hitting its output-doubling target, or a real AI-data-center or defense order landing; the risks to respect are a technical or manufacturing stumble, a slipping ~2028 timeline, or a large capital raise before revenue arrives, and with zero revenue there is no valuation floor below the ~$1.35/share of net cash — watch the milestones and the quarterly burn

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Medpace Holdings (MEDP) Q2 2026 — Medpace Holdings (MEDP), the elite full-service contract research organization (CRO) that runs clinical trials for biotech and pharma, reported a strong Q2 2026: GAAP diluted EPS of $4.25 beat the ~$3.98 estimate on revenue of $707.3M (+17.2% YoY, from $603.3M). For a CRO the whole story is bookings — and net new business awards jumped 28% to $795.7M, a 1.13x book-to-bill, while EBITDA rose ~18% to $153.4M. Management RAISED full-year guidance to revenue of $2.81B-$2.89B and GAAP EPS of $17.25-$17.95. The stock popped ~17% on the print to ~$528 (still ~16% below its $629 high). The catch: after that pop, our owner-earnings DCF pegs fair value near $540 — essentially at the price — and the demand base (mid-size biotech funding) is cyclical, with backlog up just 4.9% versus revenue up 17%. Our call: HOLD.

Medpace is one of the best businesses in healthcare that most investors have never heard of — the elite, founder-led CRO that biotech and pharma hire to design and run their clinical trials. Q2 2026 was a statement quarter: GAAP EPS of $4.25 beat ~$3.98, revenue grew 17.2% to $707.3M, EBITDA rose ~18% to $153.4M, and — the number that matters most for a CRO — net new business awards jumped 28% to $795.7M (a 1.13x book-to-bill). Management RAISED full-year guidance (revenue $2.81-2.89B, EPS $17.25-17.95), and the stock popped ~17% on the print to ~$528. After a scary stretch where biotech funding froze and the stock was nearly halved from $629 to $373, growth is clearly back. So the question isn't quality — it's price. We value Medpace on an owner-earnings DCF (normalized FCF ~$580M/yr, net cash, ~28.5M shares) across two paths: a cyclical case (+9%->4%) worth ~$408-574 and a reacceleration case (+14%->5%) worth ~$535-785. Cyclical-weighted, our central fair value lands near $540 — essentially on top of the $528 price. Three honest tells keep us cautious: backlog grew only 4.9% while revenue grew 17% (coverage is thinning, so book-to-bill must stay above 1); the company slowed its own buyback sharply (~$295M in Q2 versus $913M in 1H 2025) as the stock recovered; and part of the cash flow is flattered by customer advances. The whole thesis rests on something Medpace doesn't control: whether biotech funding stays open. Our call: HOLD, 3/5 — an elite operator with real momentum, but no margin of safety after the pop. We actually AGREE with Wall Street here (consensus Hold, ~$503 average target that already sits below the price). Own the quality; add on weakness toward the mid-$400s. Watch bookings and book-to-bill every quarter. Not financial advice.

THE CALL: HOLD (3/5, AN ELITE CRO WHOSE GROWTH ROARED BACK — BUT FAIRLY PRICED AFTER A 17% POP, WITH NO MARGIN OF SAFETY) — base-case value ~$540 vs ~$528 today.

What to watch: hard evidence the biotech-funding recovery is durable — two or three more quarters of book-to-bill above 1.1x, awards still climbing, and backlog finally growing in line with revenue — which would validate the reacceleration path (~$637 at 9%) and justify paying up; the risk to respect is the opposite, a biotech funding freeze that stalls net new awards and lifts cancellations, which at ~30x forward earnings could re-rate the stock hard

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

CSX Corporation (CSX) Q2 2026 — CSX Corporation (CSX) reported a record Q2 2026: revenue rose 10% YoY to a record $3.94B, diluted EPS of $0.54 beat the ~$0.52 estimate (+23% YoY), and net earnings rose 21% to ~$1.0B. The star was efficiency — the operating ratio improved 240 bps to 61.7% (best-in-class) as operating income jumped 17% to $1.51B and non-fuel costs fell 2% even as volume grew 6%. New CEO Steve Angel's turnaround is real: intermodal won containers off the highway (+9% volume), merchandise grew 8% to $2.45B on +4% pricing, and export coal (+12%) lifted total coal +9% despite domestic utility coal falling 2%. But roughly $190M of the revenue growth was fuel surcharge on a +74% diesel spike (intermodal's +26% revenue is mostly surcharge, not core price), and service quietly slipped (terminal dwell worse, on-time down) as the railroad ran lean. CSX RAISED full-year guidance across the board — mid-to-high-single-digit revenue growth, operating-margin expansion of more than 350 bps, and free-cash-flow growth above 80% (1H free cash flow before dividends jumped to $1.6B from $0.4B). It raised the dividend 8% to $0.14/qtr (~1.1% yield) but sharply slowed buybacks as the stock rose (~$5.7B still authorized). The stock has run ~57% off its $31.80 low to near a record high around $50 (52-wk high $51.29) — and a big part of that is a merger bet: after Union Pacific agreed to buy Norfolk Southern (~$85B), the market bet CSX is next, and CSX is even paying advisers to weigh its options. But a deal faces years of Surface Transportation Board hurdles (no UP-NS decision until 2027) and the most-cited buyer, Berkshire's BNSF, publicly said no. Our owner-earnings DCF values the railroad itself near $41 — about 18% below the price. Our call: HOLD, 2/5 — more cautious than the Street (a Buy consensus, but even its ~$48 average target now sits below the price).

CSX is one of only two railroads that blanket the eastern United States — a wide-moat franchise you physically cannot rebuild. Q2 2026 was a record: revenue rose 10% to $3.94B, diluted EPS of $0.54 beat the ~$0.52 estimate (+23% YoY), net earnings rose 21% to ~$1.0B, and the all-important operating ratio (operating costs as a share of revenue, so lower is better) improved 240 bps to a best-in-class 61.7%. That's the work of new CEO Steve Angel, ten months into a genuine turnaround: operating income jumped 17% to $1.51B and non-fuel costs actually fell 2% even as volume grew 6% and headcount fell about 6%. Under the hood the mix is nuanced — merchandise (the $2.45B core) grew 8% on real pricing, intermodal won volume off the highway (+9%), and export coal (+12%) masked a still-shrinking domestic coal book (-2%) — but roughly $190M of the top-line growth was fuel surcharge on a +74% diesel spike, so intermodal's headline +26% revenue is mostly surcharge, not core price, and service quietly slipped as the railroad ran lean. Management RAISED full-year guidance across the board (revenue growth mid-to-high-single-digit, operating-margin expansion >350 bps, free-cash-flow growth >80%), raised the dividend 8% to $0.14/qtr, and kept ~$5.7B of buyback authorized — but tellingly slowed repurchases sharply as the stock climbed. So the debate isn't the quarter. The stock has run ~57% off its $31.80 low to near a record high around $50, and a big slice of that is a takeover bet: after Union Pacific agreed to buy Norfolk Southern for ~$85B, investors decided CSX must be next, and CSX is even paying advisers to explore its options. But a deal is years away, if it comes at all — even the UP-NS merger won't clear the Surface Transportation Board until 2027, under rules that demand a combination enhance competition, and the buyer everyone names (Berkshire's BNSF) publicly said no. Value the railroad on its own merits with an owner-earnings DCF and, even leaning to the optimistic turnaround path at a fair 9% discount, fair value lands near $41 — about 18% below the ~$50 price. The ~$9 gap is the merger premium. Our call: HOLD, 2/5 — a wonderful railroad running better than it has in years, but at a record high carrying a premium the math can't justify. We're more cautious than the Street, whose Buy consensus now carries an average target (~$48) that itself sits below the price. Own it for the quality on a pullback toward the low $40s; don't chase the lottery ticket. Not financial advice.

THE CALL: HOLD (2/5, A GENUINE TURNAROUND AT A MERGER-PREMIUM PRICE — RECORD RESULTS, BUT NO MARGIN OF SAFETY AT A RECORD HIGH) — base-case value ~$41 vs ~$50 today.

What to watch: proof the operational turnaround compounds without a deal — the operating ratio grinding toward the high-50s on clean, well-served quarters (not fuel-flattered growth), and free cash flow marching toward the raised >80% guide — which would let CSX grow into its multiple and could prompt an upgrade; the risks to respect are the merger premium deflating (no bidder emerges, or the Surface Transportation Board signals it won't allow further transcontinental Class I consolidation) or service problems forcing costs back up, either of which could re-rate a record-multiple stock hard toward our ~$41 fair value

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

International Business Machines (IBM) Q2 2026 — IBM (IBM) reported a genuine miss for Q2 2026 that it pre-announced 8 days early on July 14 — triggering a 25% single-day crash, its worst day on record (bigger than the 1987 crash; records go back to 1968) and roughly $60B of market value wiped out. Revenue was $17.16B, up just 1% YoY and about $700M short of the ~$17.86B consensus; operating (non-GAAP) EPS of $2.93 (+5% YoY) missed the ~$3.01 estimate, while GAAP EPS was just $2.27 (-2% YoY) — the $0.66 gap is mostly amortization of acquired intangibles ($0.58/sh) from IBM's acquisition spree ($10.5B spent YTD). Software grew 5% to $7.8B (Red Hat +11%, Data +19%, Transaction Processing -8%); Consulting was flat at $5.3B; Infrastructure fell 7% to $3.8B as the IBM Z mainframe collapsed 42% amid a global memory-chip shortage that pushed clients to defer software and mainframe orders. Q2 free cash flow was $2.5B (down $0.3B YoY) and 1H FCF was $4.8B (flat). IBM cut FY26 constant-currency revenue growth guidance to 4-5% (from above 5%) but kept its free-cash-flow guide of +$1B YoY (to ~$15.5B) — a heavily back-half-loaded ramp. The board raised the dividend to $1.69/qtr (30th straight annual increase; ~3.3% yield, ~2.5x FCF-covered; paid since 1916). At ~$206 (a fresh 52-week low, ~38% below June's $332 all-time high) our owner-earnings DCF lands fair value near $220. Our call: HOLD, 3/5 — more cautious than the Street's split Buy consensus and ~$285 average target.

IBM is the original blue chip — a 90-year-old technology giant that pays a dividend it has never cut since 1916, with mainframes that still run the world's banks, airlines and credit-card networks. Q2 2026 was the quarter that broke it. On July 14, IBM did something companies almost never do: it pre-announced a bad quarter 8 days early. The stock crashed 25% in a single session — its worst day on record, a bigger drop than even the 1987 crash — wiping out roughly $60B of value. The July 22 print confirmed the damage: revenue of $17.2B grew just 1% and missed the ~$17.86B the Street wanted; operating EPS of $2.93 (+5%) missed the ~$3.01 estimate; and GAAP EPS was only $2.27, the $0.66 gap mostly amortization of IBM's $10.5B-a-year acquisition habit. The wreck was concentrated: the IBM Z mainframe collapsed 42% as a global memory-chip shortage pushed clients to hoard scarce components and defer big orders, and Consulting went dead flat as generative AI starts to eat its own routine work. One bright spot: Software still grew 5% (Red Hat +11%, Data +19%) — the high-margin, recurring engine that is the real reason to own IBM. Management cut full-year revenue growth guidance to 4-5% constant currency (from above 5%) but insisted free cash flow will still rise ~$1B to ~$15.5B on AI-driven productivity — a promise that loads the entire ramp onto a second half after a flat first half. The dividend (raised to $1.69/qtr, a 30th straight increase, ~3.3% yield) is safe, covered ~2.5x by free cash flow. So the debate isn't whether IBM stumbled — it clearly did. It's whether a 25% crash turned a priced-for-perfection stock into a bargain, or just a fair price for a slow-growth company. Our owner-earnings DCF frames two futures — a steady, software-led path and a stall path where mainframe stays weak and AI erodes consulting — and at 9% a 50/50 blend lands right around today's $206 price. We nudge fair value to ~$220 for the safe dividend you collect while you wait. Our call: HOLD, 3/5 — a fallen blue chip at roughly fair value, more cautious than the Street's split Buy and ~$285 average target (being cut daily). Own it for the income and the software; wait for proof the cash ramps before chasing. Not financial advice.

THE CALL: HOLD (3/5, FAIRLY VALUED AFTER THE WORST CRASH IN ITS HISTORY — A SAFE DIVIDEND, BUT A GENUINE SHOW-ME STORY) — base-case value ~$220 vs ~$206 today.

What to watch: evidence the memory-shortage air-pocket is temporary rather than structural — specifically second-half free cash flow ramping to the ~$15.5B full-year guide, IBM Z mainframe orders stabilizing, and Consulting bookings holding as generative AI reshapes the work — which would confirm the deferred demand is returning and flip us to a buy; the risks to respect are free cash flow missing the guide (a flat first half makes the back-half ramp a real question) or Consulting sliding as AI automates it, either of which would confirm the stall case and pull fair value toward $180

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Alphabet Inc. (GOOGL) Q2 2026 — Alphabet (GOOGL) reported a superb operating Q2 2026: revenue rose 24% YoY to $119.8B (its 12th straight double-digit quarter), operating income jumped 30% to $40.8B and operating margin expanded 2 points to 34%. Google Cloud was the star — revenue +82% to $24.8B with operating margin more than doubling to 35.6% (from 20.7%), proof the AI infrastructure is monetizing. Google Search & other grew 17% to $63.3B and YouTube ads +13% to $11.1B. But the headline $9.11 GAAP EPS (+294%) is misleading: $6.26 of it came from a one-time $99.0B unrealized gain on equity securities — the real operating EPS was ~$2.85 (beating the ~$2.64 estimate). The catch: capex hit $44.9B (+100% YoY) and management RAISED full-year 2026 capex guidance to $195-205B with more coming in 2027, pushing quarterly free cash flow to NEGATIVE $5.9B even as GAAP profit hit a record. To fund the build, Alphabet raised ~$50B of new equity/preferred, took on $20B of new debt, and halted buybacks. The stock — up ~117% off its $188 low to a $409 record, then down ~16% to $342 — fell another ~5% after-hours on the capex hike. At ~$342 our owner-earnings DCF lands fair value near $320. Our call: HOLD, 3/5 — more cautious than the Street's Buy consensus and ~$420 average target.

Alphabet is a $4.1 trillion colossus — the parent of Google Search, YouTube, Android, and one of the fastest-growing clouds on the planet. Q2 2026 was, operationally, a showcase: revenue +24% to $119.8B, operating income +30% to $40.8B (34% margin), and Google Cloud accelerating to +82% growth ($24.8B) with its operating margin more than doubling to ~36% — the clearest proof yet that the AI spend is monetizing. Search grew 17% (AI Overviews and Gemini are driving MORE queries), YouTube ads +13%, and the Gemini app now has 950M monthly users with ~90% of the Fortune 100 on Gemini Enterprise. But the story has a twist. The headline $9.11 EPS (up 294%) is 69% air — $6.26 of it is a one-time unrealized gain on Alphabet's equity stakes ($99.0B pre-tax); the real operating number is ~$2.85. And beneath the record profit, free cash flow went NEGATIVE (-$5.9B) as capex exploded to $44.9B (+100% YoY) and management raised full-year capex guidance to $195-205B, with more coming in 2027. To fund the build Alphabet raised ~$50B of new stock/preferred, doubled long-term debt to $98B, and halted buybacks entirely. The stock fell ~5% after-hours on the capex hike. So the debate isn't quality — it's price and cash. At ~$342 the market already discounts a decade of ~10%+ owner-earnings growth AND assumes that record AI capex earns its keep. Our owner-earnings DCF (a cautious path ~$230 and an AI-compounder path ~$375 at 9%) blends to a fair value near $320 — below the price, and right at the after-hours level. Our call: HOLD, 3/5. A generational business with the best full-stack AI hand in tech, but priced today for the payoff, not the risk. We're the cautious outlier versus the Street's Buy consensus and ~$420 average target (+23%). Add on real weakness toward the high $200s. Not financial advice.

THE CALL: HOLD (3/5, A GENERATIONAL BUSINESS, PRICED FOR THE PAYOFF — A SHOWCASE QUARTER WITH NEGATIVE FREE CASH FLOW) — base-case value ~$320 vs ~$342 today.

What to watch: proof the AI capex is earning its keep — specifically Google Cloud's operating margin holding or expanding from ~36%, and free cash flow inflecting back to positive as revenue growth outruns capex — which would justify the premium and prompt an upgrade; the risks to respect are capex climbing again in 2027 with free cash flow still negative, or an antitrust ruling forcing real changes to Search/ad-tech, either of which could re-rate a stock that already discounts a decade of double-digit owner-earnings growth

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ServiceNow (NOW) Q2 2026 — ServiceNow (NOW), the enterprise-workflow and AI platform run by most of the Fortune 500, reported a Q2 2026 beat-and-raise: non-GAAP EPS of $0.90 topped the ~$0.86 estimate (+23% YoY) on total revenue of $3.99B (+24% YoY); subscription revenue was $3.88B (+24.5% YoY, +23% cc). cRPO reached $13.20B (+21% YoY) and total RPO $29.0B (+21%). Non-GAAP operating margin was 29.5% (3 pts above guidance) and free cash flow was $634M (16% margin, seasonally Q1-loaded). ServiceNow AI crossed $1B in annual contract value with agentic deployments up 9x in nine months; the company closed 123 net-new $1M+ ACV deals (+~40% YoY) and ended with 658 customers >$5M ACV (+23%). Management raised FY2026 subscription guidance for the second time to $15.76-15.78B (+22.5%), guiding a 31.5% non-GAAP operating margin and a 35% FCF margin (CEO Bill McDermott's 'Rule of 56'). The catch: GAAP EPS was just $0.29 (net income $298M) as GAAP operating margin fell to 4% (from 11%) on Armis/Veza/Moveworks acquisition amortization and stock-based comp of 16.5% of revenue; and cRPO growth is guided to decelerate to 19.5% next quarter. Yet after a 5:1 split (Dec 2025) the stock has de-rated ~55% from its ~$211 high to ~$95 (down 38% YTD) and fell another 6.5% on the print — to ~24x forward earnings and a 5.7% FCF yield. Our owner-earnings DCF (haircut for stock-comp dilution, deceleration modeled) lands fair value near $150. Our call: BUY, 4/5.

ServiceNow is one of the premier software franchises on earth — the single platform that runs digital workflows (IT, HR, customer service, security) across the vast majority of the Fortune 500, on multi-year contracts with enormous switching costs. Q2 2026 was a genuine beat-and-raise: non-GAAP EPS of $0.90 beat the ~$0.86 estimate (+23% YoY), total revenue rose 24% to $3.99B, subscription revenue grew 24.5% to $3.88B, and the non-GAAP operating margin of 29.5% came in 3 points above guidance. The backlog is enormous — total RPO of $29.0B (+21%) and cRPO of $13.20B (+21%) — and the AI story finally has a number: ServiceNow AI crossed $1B in annual contract value, with agentic deployments up 9x in nine months, the fastest new-product ramp in company history. Management raised full-year subscription guidance for the second time to $15.76-15.78B (+22.5%), targeting a 31.5% non-GAAP operating margin and a 35% free-cash-flow margin (the 'Rule of 56'). So why did the stock FALL 6.5% on the print? Because the market has been de-rating it for a year: adjusted for December 2025's 5-for-1 split, NOW has fallen ~55% from its ~$211 high to ~$95 (down 38% YTD), from ~60x forward earnings to about 24x. The bears have real points — cRPO growth is guided to decelerate to 19.5% next quarter, GAAP EPS is only $0.29 (GAAP operating margin collapsed to 4% on M&A amortization), and stock-based comp runs 16.5% of revenue, so the $0.90 'adjusted' number flatters the true economics. But here is the striking part: even our conservative owner-earnings DCF — free cash flow haircut for stock-comp dilution, and modeling steady deceleration — lands fair value near $150 against a $95 price, with a 10% discount-rate base case still at ~$137. You don't need the AI dream to work for the stock to be cheap; you just need a maturing category leader to decelerate gracefully. This is a case of letting the math override the mood: a world-class compounder with intact fundamentals, cut nearly in half, now offering a real margin of safety. Our call: BUY, 4/5 (not a 5 because deceleration and dilution are genuine risks). Wall Street agrees — a Buy consensus (59 buy / 9 hold / 1 sell, 69 analysts) with a ~$140 average target (+47%). Watch cRPO and the AI ACV number every quarter to confirm the thesis. Not financial advice.

THE CALL: BUY (4/5, ELITE COMPOUNDER, DE-RATED TO A DISCOUNT — A BEAT-AND-RAISE THE MARKET HATED, NOW AT ~24x FORWARD EARNINGS WITH A REAL MARGIN OF SAFETY) — base-case value ~$150 vs ~$95 today.

What to watch: ServiceNow AI annual contract value compounding from $1B toward $5B and cRPO growth stabilizing back above 20% — proof the deceleration is bottoming and the AI layer is offsetting platform maturity — which would confirm the compounder path and support a re-rating back toward the Street's ~$140 target and our ~$150 fair value; the risk to respect is subscription growth sliding into the mid-teens with no AI offset, or elevated stock-based compensation (16.5% of revenue) and continued acquisition-driven dilution eroding owners' share, which at a still-premium GAAP multiple could keep the stock out of favor even as the business compounds

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.